Membership Directory

BIND Therapeutics

Category: Drug Development
Phone: (617) 491-3400
Fax: (617) 491-0357
Location: Cambridge, MA

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted therapeutics. We are leveraging our Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer. Additionally, we have announced collaborations with Amgen, Inc., Pfizer Inc., and AstraZeneca AB to develop Accurins based on molecularly targeted APIs from their product pipelines. We are looking for highly motivated people who thrive on being challenged and working in a highly collaborative environment to join the team and play a key role in conducting rigorous, cutting-edge science.

Back to list